Trials / Terminated
TerminatedNCT06585150
Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
A Phase 2 Randomized, Placebo-controlled Study of the Safety and Efficacy of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it is in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers want to see if obeldesivir can help participants' symptoms get better faster. The primary objectives of this study are to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Obeldesivir | Tablet administered orally |
| DRUG | Obeldesivir Placebo | Tablet administered orally |
Timeline
- Start date
- 2024-10-14
- Primary completion
- 2025-05-08
- Completion
- 2025-06-09
- First posted
- 2024-09-05
- Last updated
- 2025-07-28
Locations
121 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06585150. Inclusion in this directory is not an endorsement.